top of page

Board of Directors

Jayne Shaw image.jpg

Jayne Shaw

Executive Chair

Trained as a Registered Nurse in the UK, on arrival in Australia she became a Director of Nursing and Chief Executive Officer of two private hospitals. Following this she established an Australian and International  consulting business which was sold to Healthsouth a large US Healthcare company. After  this she became the Co-founder of Vision Group an Opthalmic Doctor equity consolidation model which was successfully listed on the ASX.

 

Jayne joined a number of private Healthcare Boards involved with specialist consolidation including Cardiology, Orthopaedics, and Women’s Health she continued to work with Private Equity firms on local and International Healthcare transactions. Jayne is a co-owner of Sydney Breast Clinic and a co-founder of BCAL Diagnostics. Current Board positions are The Citadel Group, Ellerston JAADE Australian Private Assets Fund, Mable Technologies, Corum Group. She is also the Non-Executive director of Pinnacle Charitable Foundation and Prospection.

Ron Phillips.jpg

The Hon Ron Phillips (AO)

Biospecimen and Clinical Research

Following 15 years in the NSW Parliament which included serving as Minister for Health and Deputy Leader of the Opposition, Ron developed a successful consulting business in the Health and Aged Care Industry.

His business interests included co-owner and Managing Director of Sydney Breast Clinic which he sold to Healthscope. He currently serves as Chair of the Sydney Local Health District and as Director on Westmead IVF.

Jonathan-Trollip.jpg

Jonathan Trollip

Independent Non-Executive Director

Independent Non-Executive Director

Jonathan is a globally experienced independent director with over 30 years commercial, corporate, governance and legal and transactional expertise. Jonathan is currently non-executive independent chairman of ASX listed Global Value Fund Ltd,  Plato Income Maximizer Limited  and Spheria Emerging Companies limited. He is a non-executive director of  LSE, JSE and ASX listed Kore Potash Limited and holds private company directorships in the commercial and not-for-profit sectors. He was formerly non-executive independent chairman of ASX listed Future Generation Investment Company Ltd , Antipodes Global Investment Company Ltd and Spicers Limited and non-executive director of Prople Funeral Partners Limited.

Jonathan was a principal of Sydney, Australia based structured finance group Meridian International Capital Limited for over 20 years, Prior to that, Jonathan was a partner with law firm Herbert Smith Freehills. Jonathan is a Fellow of the Australian Institute of Company Directors.

David Darling.jpg

David Darling

Non-Executive Director

David Darling is a highly credentialed leader and executive who brings a wealth of commercial experience to BCAL from his prior role as CEO of Pacific Edge, a NZX50 and ASX listed business focused on commercialising its bladder cancer diagnostics tests across global markets, with commercial operations in New Zealand, Australia, Singapore and the USA. Prior to Pacific Edge, Mr Darling held senior management positions with Fletcher Challenge. 

Mr Darling has a background as a scientist with a specialty in genetics and has more than three decades of experience in developing and commercialising life sciences and biotechnology products.

Mark.JPG

Mark Burrows AO

Independent Non-Executive Director

Mark Burrows AO | After a distinguished global career in investment banking, Markbecame an advocate for private sector involvement for sustainable development and the evolution of green finance.

 

Mark has held senior advisory roles with UNEP, UNDP, The Green Finance Initiative London, G20 Sustainability Group and currently on the Asian Board of the Nature Conservancy.

Hero-Shot-Photography-_E0A8838.jpeg

John Hurrell

Independent Non-Executive Director and Consultant.

Dr Hurrell has developed and successfully commercialised multiple products and services in life sciences and diagnostics over a career in the industry spanning more than 35 years. He has developed and managed start-up and early-stage companies including successful life science companies based on university developed technologies. Most notably Dr Hurrell spent almost 7 years in managerial and executive roles with NYSE-listed, Fortune 500 clinical laboratory company Quest Diagnostics. Within Quest’s subsidiary Focus Diagnostics, he led the development and launch of more than 70 molecular diagnostics tests and successfully gained 510(k) approvals for 6 products. He also served as VP of Business Development at Quest Diagnostics.

Executive Team

Shane_Ryan_BCAL-0256_edited.jpg

Shane Ryan, MBA

Chief Executive Officer

Shane Ryan, former Global SVP of Strategy & Innovation - Patient Access at GenesisCare, boasts 20+ years in global oncology, specialising in breast cancer. With a vast oncology network, he excels in patient care, research, and innovative service models. His contributions include precision medicine tests and clinical trials for high-risk breast cancer. Previously, he held executive roles at Peter MacCallum Cancer Centre for a decade.

Hero-Shot-Photography-_E0A9288.jpeg

Dr Amani Batarseh, PhD

Chief Scientific Officer

Dr Amani Batarseh is the company’s Chief Scientist. She graduated magna cum laude from La Roche College in Pennsylvania where she had a Pacem in Terris scholarship for academic excellence. Later, she received a fellowship to purse her PhD at Georgetown University, Washington, DC in Biochemistry and Molecular & Cellular Biology. Amani completed post doctoral studies at Harvard University, McGill University and Wollongong University. During her time in Canada, Amani managed and established two mass spectrometry laboratories being at the Research Institute of McGill University Hospital and The Glen Hospital in Montreal, respectively. Her versatile profile of expertise combines molecular biology with lipidomics and mass spectrometry to answer biological questions.

Kathy Koskiris

BSc. MBA.​ Director, Clinical Laboratory Services​

More than 20 years experience in building and managing clinical laboratories under TGA and US CLIA regulations. Managed CLIA certification for multiple new products, CLEP certification​ and NATA Accreditation with ISO15189 & NPAAC standards.​

05CB6D9A-A0C1-4C5C-867F-EAAF4A204F9B.png

Guy Robertson

Chief Financial Officer & Company Secretary

A Finance Director/Chief Financial Officer for a number of companies within the Jardine Matheson Group over a period of 16 years. Guy provided CFO consulting services to many large corporations and SMEs. CFO/Company Secretary for a number of Australian public companies including Evogenix Limited and is currently a Director of ASX-listed entities Metal Bank Limited and Hastings Technology Metals Ltd.

 

Company Secretary for Bioxyne Limited, Artemis Resources Limited and Truscreen Limited

Hero-Shot-Photography-_E0A8920.jpeg

Alison Cook (Mew), MSc 

Quality and Regulatory Advisor

Management and leadership experience of more than 30 years across the biopharmaceutical, diagnostic and health service sectors. Spent 13 years in senior executive roles at CSL Limited. Consulted widely across the life sciences industry,.

Scientific Advisors 

kim ekroos.jpg

Dr Kim Ekroos, PhD

Lipidomics and Mass Spectrometry

Kim Ekroos is the founder and CEO of Lipidomics Consulting Ltd., a consulting business providing unique services for customers globally in the field of Lipidomics. He received his Ph.D. degree in biology from the Technical University in Dresden, Germany, in 2003. His expertise includes high-throughput technologies for the precise assessment of lipidomes enabled by advanced mass spectrometry, automation, and software tools towards discovery of biological architectures and of diagnostic biomarkers for clinical purpose.
Kim is a globally experienced independent consultant for Lipidomics with over 20 years academics, healthcare and industry expertise. He has a number of patents for biomarker discovery, numerous peer-reviewed publications and an editor of a widely read Lipidomics book. He is the current president of the newly founded International Lipidomics Society (ILS) to which the Lipidomics Standards.

craig_gedye_768.jpg

A/Prof Craig Gedye
BSc(Hons), MBChB, FRACP, PhD

Biospecimen and Clinical Research

Craig Gedye is a medical oncologist and cancer researcher. He works for people with melanoma, brain, prostate, bladder and kidney cancers at the Calvary Mater Newcastle and is the Clinical Research Director at the NSW Health Statewide Biobank.
His research in the School of Medicine and Public Health at the University of Newcastle/Hunter Medical Research Institute focuses on complexity and heterogeneity in cancer – "why are cancers different between different people; why are cancers cells different to each other; what does this mean for each person’s treatment?"
Craig is leading several national cancer clinical trials for the ANZUP and COGNO trials groups, and is a member of the Mark Hughes Scientific Advisory Committee, HNEHLD Clinical Trials Ethics Subcommittee and ANZUP Cancer. He has been awarded numerous scholarships, fellowships, grants, investigator-initiated clinical trials, publications, conference presentations and prizes.

SanjayWarrier80-2-e1605494865917.jpeg

Dr. Sanjay Warrier (Associate Prof.)BSc (Med) MBBS FRACS MS

Consultant Breast Oncology and Oncoplastic Surgeon

Consultant Breast Oncology and Oncoplastic Surgeon at Chris O’Brien Lifehouse, Royal Prince Alfred and Mater Hospitals. He is also a Visiting Medical Officer at BreastScreen NSW.

 

An Associate Professor of the University of Sydney with the Royal Prince Alfred Academic Institute. He is lead researcher at the Institute with goals of developing and creating a culture of academia within the Breast Department.

 

Won the Patron’s Prize at the Royal Prince Alfred Hospital for best scientific research. Sanjay has also published many papers and co-authored articles in peer reviewed journals and magazines. Sanjay is Chairman of Post-Fellowship Training for BreastSurgANZ, a role that involves training future breast surgeons in Australia and New Zealand.

A214CC8B-C7A5-4D13-A5CF-285E52419B36.png

Prof. Peter Meikle, PhD

Baker IDI Lipidomics Melbourne

Peter is an NHMRC Senior Research Fellow at the Baker Institute. He leads the Obesity and Diabetes Program and is Head of the Metabolomics laboratory. He is also Editor in Chief of the journal Metabolites and holds affiliate positions at the University of Melbourne, Monash University and the NHMRC Clinical Trials Centre, University of Sydney.

 

The Metabolomics laboratory uses state of the art tandem mass spectrometry to obtain metabolic profiles from cell and animal models in addition to clinically relevant human samples. This approach is providing an improved understanding of disease mechanisms leading to new biomarkers for improved diagnosis and risk assessment as well as new therapeutic strategies in the areas of obesity, diabetes and cardiovascular disease.

Hero-Shot-Photography-_E0A9151.jpeg

Dr. Mary Rickard OAM
MBBS, BSc(Med)(HonsII), DRACR, DDU, MPH, RANZCR

Radiology Clinical Advisor

Dr Mary Rickard received a Member of the Order of Australia award in 2002, for service to medicine through the integration of population-based screening for early detection of breast cancer, and the development of education programs for health professionals.

She is also involved in consulting with numerous breast screening and diagnostic training programs across South East Asia, in particular Singapore, Indonesia, Malaysia, Thailand, Japan and most recently Mongolia.

Scientific Team

Hero-Shot-Photography-_E0A9351.jpeg

Dr Desmond Li

Senior Research Scientist

Dr Desmond Li completed his PhD at The University of Sydney, exploring protein, metabolite and lipid markers for the development of type 2 diabetes by mass spectrometry.

 

He conducted post doctoral studies at the Heart Research Institute, Australia, applying his mass spectrometry skills in the context of heart failure. Prior to his PhD, Desmond has worked in analytical labs gaining skills in routine testing, quality management and lab management.

 

His interests are in applying mass spectrometry techniques to further understand human diseases.

Ameline.jpg

Dr Ameline Lim

Dr. Ameline Lim completed her PhD at the University of New South Wales. Her research focused on using mass spectrometry in characterizing a lipid enzyme inhibitor on human and mouse lipidome. Her extensive training led her to a postdoctoral study involving phase II clinical trials, gaining valuable insights into the clinical research environment. She subsequently joined Prince of Wales Hospital Chemical Pathology lab where she was the second in charge of the mass spectrometry unit gaining skills in diagnostic lab operations and analytical method development.  

Ameline is passionate about leveraging her skills and experience to drive impactful innovations in research and healthcare industries.  

Hero-Shot-Photography-_E0A9242.jpeg

Kerry Heffernan

Senior Research Assistant

Kerry is the company’s Research Assistant. Kerry recently graduated with First Class Honours from the University of Sydney. He presented his Honours project at the 2019 ASCEPT-PAGANs conference in Queenstown NZ.


Kerry as a diverse range of professional interests including health, carcinogenesis, machine learning, programming and metabolomics.

IMG_2070 (2).JPG

Dr David Peak, PhD

USA Scientific Lead, Technology Transfer

Expert in Lipidomics and mass spectrometry. Expertise with both qualitative and quantitative methods.

Founder and CEO of Peake performance, a lipidomics consulting company in the USA.

 

Previously the global lead for lipidomics and metabolomics at Thermo Fisher Scientific, one of the largest mass spectrometry and life sciences in the world. 

BCAL Other Key Members

unnamed.jpg

Charlie Lewis

Corporate Finance Advisor

Charlie has 30 years of global capital raising and mergers and acquisitions experience.  After a career holding senior positions at Baring Brothers, Macquarie Bank, Investec and EY, working in Australia, SE Asia, South Africa and the UK, he now runs an independent advisory boutique. 

 

Charlie has an M&A in Economics from Cambridge University, is a Fellow of the Institute of Chartered Accountants in England and Wales and is a Graduate of the Australian Institute of Company Directors.

bottom of page